非小细胞肺癌（NSCLC）是肺癌最常见的亚型，具有较高的转移性扩散率和耐药性。因此，NSCLC患者预后非常差，存活机会非常低。人类肿瘤与调节的细胞死亡（RCD）密切相关，如凋亡、自噬、铁死、焦亡和坏死斑块。目前，针对各种类型RCD的小分子化合物已显示出作为抗癌治疗的潜力。此外，RCD似乎是抗肿瘤免疫应答的特定部分。因此，将RCD与免疫疗法相结合可能增加治疗对肿瘤生长的抑制效果。在本综述中，我们总结了用于NSCLC治疗的小分子化合物，重点关注RCD和药理系统。此外，我们描述了一个RCD为基础的免疫治疗联合方案在NSCLC中的当前研究状况，为将来针对RCD与免疫疗法相结合靶向NSCLC病人提供新的思路。© 2023 John Wiley & Sons A/S. 由John Wiley & Sons Ltd.出版。

Non-small-cell lung cancer (NSCLC), which has a high rate of metastatic spread and drug resistance, is the most common subtype of lung cancer. Therefore, NSCLC patients have a very poor prognosis and a very low chance of survival. Human cancers are closely linked to regulated cell death (RCD), such as apoptosis, autophagy, ferroptosis, pyroptosis, and necroptosis. Currently, small-molecule compounds targeting various types of RCD have shown potential as anticancer treatments. Moreover, RCD appears to be a specific part of the antitumor immune response; hence, the combination of RCD and immunotherapy might increase the inhibitory effect of therapy on tumor growth. In this review, we summarize small-molecule compounds used for the treatment of NSCLC by focusing on RCD and pharmacological systems. In addition, we describe the current research status of an immunotherapy combined with an RCD-based regimen for NSCLC, providing new ideas for targeting RCD pathways in combination with immunotherapy for patients with NSCLC in the future.© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.